Drug Trial Radar · NCT03502148
Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Oct 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Jun 19, 2018
Primary completion
Oct 27, 2019
Study completion May 6, 2020
Sponsor
- Lead sponsor
- Privo TechnologiesIndustry
- Sponsor type
- Industry
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Apr 18, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Up to 31 subjects diagnosed with oral squamous cell carcinoma received one application of a permeation enhancer 3 treatment applications of a Cisplatin drug-loaded patch to the tumor site at each of the 4 treatment visits. These 4 treatment visits were scheduled to occur during the 3 weeks prior to the standard of care tumor resection. Funding Source: FDA OOPD
Conditions
- Oral Squamous Cell Carcinoma
Interventions
PRV111 (Cisplatin Transmucosal System)Drug
Each treatment visit will include one application of a permeation enhancer and then 2, 3 or 5 PRV111 (Cisplatin Transmucosal System) applications depending on the Stage subject is enrolled in.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine an Efficacious Dose (mg/cm2) of PRV111 (Cisplatin Transmucosal System) Via Number of Tumor ResponsesTime frame: Subjects were evaluated for efficacy during the 4 treatment visits in the 21 days prior to surgery
- Determine a Safe Dose (mg/cm2) of PRV111 (Cisplatin Transmucosal System) Via Number of Dose-Limiting ToxicitiesTime frame: 4 treatment visits in the 21 days prior to surgery
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Advanced ENT and Allergy
Louisville, Kentucky
University of Cincinnati Cancer Institute
Cincinnati, Ohio
Ben Taub Hospital
Houston, Texas
Memorial Hermann Hospital
Houston, Texas
The University of Texas Health Science Center School of Dentistry
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.